BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 30887178)

  • 1. TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer.
    Melisi D; Garcia-Carbonero R; Macarulla T; Pezet D; Deplanque G; Fuchs M; Trojan J; Kozloff M; Simionato F; Cleverly A; Smith C; Wang S; Man M; Driscoll KE; Estrem ST; Lahn MMF; Benhadji KA; Tabernero J
    Cancer Chemother Pharmacol; 2019 May; 83(5):975-991. PubMed ID: 30887178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer.
    Melisi D; Garcia-Carbonero R; Macarulla T; Pezet D; Deplanque G; Fuchs M; Trojan J; Oettle H; Kozloff M; Cleverly A; Smith C; Estrem ST; Gueorguieva I; Lahn MMF; Blunt A; Benhadji KA; Tabernero J
    Br J Cancer; 2018 Nov; 119(10):1208-1214. PubMed ID: 30318515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer.
    Ikeda M; Takahashi H; Kondo S; Lahn MMF; Ogasawara K; Benhadji KA; Fujii H; Ueno H
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1169-1177. PubMed ID: 28451833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics and exposure-overall survival analysis of the transforming growth factor-β inhibitor galunisertib in patients with pancreatic cancer.
    Gueorguieva I; Tabernero J; Melisi D; Macarulla T; Merz V; Waterhouse TH; Miles C; Lahn MM; Cleverly A; Benhadji KA
    Cancer Chemother Pharmacol; 2019 Nov; 84(5):1003-1015. PubMed ID: 31482224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-202 Diminishes TGFβ Receptors and Attenuates TGFβ1-Induced EMT in Pancreatic Cancer.
    Mody HR; Hung SW; Pathak RK; Griffin J; Cruz-Monserrate Z; Govindarajan R
    Mol Cancer Res; 2017 Aug; 15(8):1029-1039. PubMed ID: 28373289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway.
    Herbertz S; Sawyer JS; Stauber AJ; Gueorguieva I; Driscoll KE; Estrem ST; Cleverly AL; Desaiah D; Guba SC; Benhadji KA; Slapak CA; Lahn MM
    Drug Des Devel Ther; 2015; 9():4479-99. PubMed ID: 26309397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma.
    Wick A; Desjardins A; Suarez C; Forsyth P; Gueorguieva I; Burkholder T; Cleverly AL; Estrem ST; Wang S; Lahn MM; Guba SC; Capper D; Rodon J
    Invest New Drugs; 2020 Oct; 38(5):1570-1579. PubMed ID: 32140889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study.
    van der Sijde F; Homs MYV; van Bekkum ML; van den Bosch TPP; Bosscha K; Besselink MG; Bonsing BA; de Groot JWB; Karsten TM; Groot Koerkamp B; Haberkorn BCM; Luelmo SAC; Mekenkamp LJM; Mustafa DAM; Wilmink JW; van Eijck CHJ; Vietsch EE; On Behalf Of The Dutch Pancreatic Cancer Group
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
    Kelley RK; Gane E; Assenat E; Siebler J; Galle PR; Merle P; Hourmand IO; Cleverly A; Zhao Y; Gueorguieva I; Lahn M; Faivre S; Benhadji KA; Giannelli G
    Clin Transl Gastroenterol; 2019 Jul; 10(7):e00056. PubMed ID: 31295152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autotaxin Secretion Is a Stromal Mechanism of Adaptive Resistance to TGFβ Inhibition in Pancreatic Ductal Adenocarcinoma.
    Pietrobono S; Sabbadini F; Bertolini M; Mangiameli D; De Vita V; Fazzini F; Lunardi G; Casalino S; Scarlato E; Merz V; Zecchetto C; Quinzii A; Di Conza G; Lahn M; Melisi D
    Cancer Res; 2024 Jan; 84(1):118-132. PubMed ID: 37738399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy.
    An X; Li YH; Lin XB; Wang FH; Feng F; Xu RH; Jiang WQ; He YJ
    Ai Zheng; 2009 Mar; 28(3):286-91. PubMed ID: 19619444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic impact of circulating miRNAs in patients with advanced esophagogastric cancer during palliative chemotherapy.
    van Zweeden AA; Opperman RCM; Honeywell RJ; Peters GJ; Verheul HMW; van der Vliet HJ; Poel D
    Cancer Treat Res Commun; 2021; 27():100371. PubMed ID: 33866108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine.
    Capper D; von Deimling A; Brandes AA; Carpentier AF; Kesari S; Sepulveda-Sanchez JM; Wheeler HR; Chinot O; Cher L; Steinbach JP; Specenier P; Rodon J; Cleverly A; Smith C; Gueorguieva I; Miles C; Guba SC; Desaiah D; Estrem ST; Lahn MM; Wick W
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28481241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma.
    Meijer LL; Garajová I; Caparello C; Le Large TYS; Frampton AE; Vasile E; Funel N; Kazemier G; Giovannetti E
    Ann Surg; 2020 Jun; 271(6):1137-1147. PubMed ID: 30394883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.
    Melisi D; Oh DY; Hollebecque A; Calvo E; Varghese A; Borazanci E; Macarulla T; Merz V; Zecchetto C; Zhao Y; Gueorguieva I; Man M; Gandhi L; Estrem ST; Benhadji KA; Lanasa MC; Avsar E; Guba SC; Garcia-Carbonero R
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33688022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine-based chemotherapy.
    Lu H; Lu S; Yang D; Zhang L; Ye J; Li M; Hu W
    Biosci Rep; 2019 May; 39(5):. PubMed ID: 30777929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer.
    Ohuchida K; Mizumoto K; Kayashima T; Fujita H; Moriyama T; Ohtsuka T; Ueda J; Nagai E; Hashizume M; Tanaka M
    Ann Surg Oncol; 2011 Aug; 18(8):2381-7. PubMed ID: 21347785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.
    Fuchs CS; Azevedo S; Okusaka T; Van Laethem JL; Lipton LR; Riess H; Szczylik C; Moore MJ; Peeters M; Bodoky G; Ikeda M; Melichar B; Nemecek R; Ohkawa S; Świeboda-Sadlej A; Tjulandin SA; Van Cutsem E; Loberg R; Haddad V; Gansert JL; Bach BA; Carrato A
    Ann Oncol; 2015 May; 26(5):921-927. PubMed ID: 25609246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.
    Hurwitz HI; Uppal N; Wagner SA; Bendell JC; Beck JT; Wade SM; Nemunaitis JJ; Stella PJ; Pipas JM; Wainberg ZA; Manges R; Garrett WM; Hunter DS; Clark J; Leopold L; Sandor V; Levy RS
    J Clin Oncol; 2015 Dec; 33(34):4039-47. PubMed ID: 26351344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma.
    Harding JJ; Do RK; Yaqubie A; Cleverly A; Zhao Y; Gueorguieva I; Lahn M; Benhadji KA; Kelley RK; Abou-Alfa GK
    Cancer Med; 2021 May; 10(9):3059-3067. PubMed ID: 33811482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.